ELMWOOD PARK, N.J.,
May 13, 2020 /PRNewswire/ --
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:
OPK), today launched the BioReference Employer Solution, a COVID-19
screening program that assists employers' decisions about
return-to-work policies.
Test results play a critical role in the fight against COVID-19
by identifying who has detectable antibodies, and providing the
amount of antibodies measured. Combining other clinical information
and guidance from health authorities, these results can inform
decisions on enhancing the safety of employees and
customers.
To support return-to-work strategies and COVID-19 antibody
screening efforts, BioReference is offering flexible specimen
collection options tailored to each employer, including a
plug-and-play program in a designated location for employees or at
one of BioReference's large pop-up sites. The first pop-up site
will open at the Livingston Mall in Livingston, New Jersey, beginning on
May 15.
Livingston Mall COVID-19 Testing Location:
112 Eisenhower Parkway, Livingston,
NJ 07039
In the parking lot between Lord & Taylor and Macy's
Mondays through Saturdays beginning May 15,
2020
8AM – 6PM
ET
The BioReference Employer Solution provides digital registration
and check-in, onsite testing and processing, and online result
access. BioReference can tailor the offering of testing depending
on an organization's size and preference, which can include site
identification and set-up services, and phlebotomy
services.
"For employers, COVID-19 screening for antibodies
is one additional piece of information to help guide decisions
about moving forward," said Jon R.
Cohen, M.D., Executive Chairman of BioReference
Laboratories. "Antibody testing can provide employers key
information about who might have been exposed or infected, and who
may potentially be immune from re-infection. It's our
responsibility to add to the body of knowledge for this virus, and
we believe antibody screening can be helpful to guide us toward a
new normal."
For more information, visit
https://www.bioreference.com/coronavirus/employers-and-government-authorities/.
About BioReference Laboratories, Inc.
BioReference
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions and medical
groups. The company is in network with the five largest
health plans in the United States,
operates a network of 10 laboratory locations, and is backed by a
medical staff of more than 160 MD, PhD and other professional level
clinicians and scientists. With a leading position in the
areas of genetics, women's health, maternal fetal medicine,
oncology and urology, BioReference and its specialty laboratories,
GenPath and GeneDx, are advancing the course of modern
medicine. For more information, visit
https://www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
BioReference's antibody screening test, the availability of the
test and the role and value of the information provided and its
impact on decisions relative to the safety of employees and
customers, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in the OPKO Health, Inc. Annual Reports on Form
10-K filed and to be filed with the Securities and Exchange
Commission and in its other filings with the Securities and
Exchange Commission. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state
regulations and legislation, the regulatory process for new
products and indications, manufacturing issues that may arise,
patent positions and litigation, among other factors. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-launches-covid-19-employer-solution-301058864.html
SOURCE BioReference Laboratories, Inc